Fundamental Analysis of Dr. Reddy’s Laboratories Ltd. - Growth / Value Index
RDY - Valuation Highlights
Valuation Analysis
Tsr Value Index - Excellent Score of 95.00
Undervalued - Price to Intrinsic Value of 0.0011
Price to Earning Ratio is 0.272 and EV to EBITDA is 0.335 suggesting company is undervalued.
Price to Book Ratio is 0.0445 indicating that it is undervalued.
Book Value in last 3 years is trending up
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 0.204 | 0.204 | -18.76 % | |
Price to Book | 0.0432 | 0.0406 | -16.70 % | 0.0406 |
Price to Sales | 0.0407 | 0.0408 | -11.60 % | |
Enterprise Value to EBITDA Multiple | 0.253 | 0.226 | -5.34 % |
RDY - Profitability Highlights
Profitability Analysis
Piotroski F Score - Excellent Value of 9.0
Earning Yield of 367.25 %
Company Earning excess return
All key Trailing Twelve Months Margin growing by 15 %
Annual Net Profit in last 3 years is trending up
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 18.39
Good Return on Equity of 16.80% is achieved by the company
Good Net Margin of 20.44% is achieved by the company
Very Low Dividend Yield of 0.710 %
EPS decline for last four quarters
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 21.73 | 19.85 | 2.54 % | 4.66 |
Return On Asset | 15.77 | 14.37 | 2.93 % | 3.37 |
Net Profit Margin | 19.94 | 19.95 | 8.81 % | 18.45 |
Operating Profit Margin | 23.79 | 23.72 | -31.68 % | 20.88 |
EBITDA Margin | 25.86 | 29.03 | -4.07 % | 26.12 |
Highlights
Market Cap | 11367.20 M |
Enterprise Value | 18290.20 M |
Price/Book TTM | 0.0432 |
Outstanding Share | 166528 K |
Float/ Outstanding Share | 71.91% |
Dividend Yield | 0.700 % |
Share Holding
Guru Numbers
Price/Graham No | 0.0192 |
Peter Lynch Ratio | 113.14 |
Piotroski F Score | 5.00 |
Altman Z Score | 2.31 |
Sloan Ratio | 0.0265 |
Peter Lynch Fair Value | 5996.15 |
RDY - Growth Highlights
Growth Analysis
Tsr Growth Index - Excellent Score of 90.56
YoY Net Margin Jump by 66.75%
Annual sales of the company is increased for three years in a row
Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 279388 M | 13.54 % | 1.83 % |
Gross Profit | 172235 M | 19.39 % | 1.71 % |
EBITDA | 72254.00 M | 8.91 % | 13.09 % |
Net Profit | 55706.00 M | 23.54 % | 5.21 % |
EPS | 334.29 | 23.09 % | NA |
RDY - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 92.19
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Company financial liquidity has improved
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.050 | -4.50 % | 0.050 |
Cash Ratio | 0.848 | 8.94 % | |
Quick Ratio | 1.92 | 5.84 % | 1.92 |
Shareholders Equity | 72.40 | 0.375 % | |
Debt to EBITDA | 0.173 | 5.64 % |
Historical Valuation Ratios of Dr. Reddy’s Laboratories Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Dr. Reddy’s Laboratories Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Dr. Reddy’s Laboratories Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Dr. Reddy’s Laboratories Ltd.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)